Federica Maria Catania
YOU?
Author Swipe
View article: Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study
Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study Open
Since the introduction of imatinib, 2nd and 3rd-generation Tyrosine Kinase Inhibitors (TKIs) with greater potency have expanded CML treatment options. Recently, the allosteric inhibitor Asciminib (ASC) has been introduced. While the goal i…
View article: Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors
Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors Open
An accurate estimation of AML prognosis is complex since it depends on patient-related factors, AML manifestations at diagnosis, and disease genetics. Furthermore, the depth of response, evaluated using the level of MRD, has been establish…